SERPINA1 and metabolic disease: On the 147th day of the experiment, inflammation and diffuse emphysema of the lungs, damage to the alveolar epithelium and endothelium, and a decrease in the concentration of alpha1-antitrypsin were revealed in mice with metabolic disorders, treated with LPS and CSE.